GlobalData identifies 10 potential pre-registration drugs as blockbusters by 2025

9 March 2020

Data and analytics firm GlobalData suggest that, out of all the drugs that are currently in the pre-registration phase and are expected to launch in 2020, 10 have the potential to reach blockbuster status over the next six years.

Amgen (Nasdaq: AMGN) and Allergan’s (NYSE: AGN) biosimilar candidate to Roche’s (ROG: SIX) Rituxan (rituximab) shows the greatest potential of these drugs. It is projected to reach almost $4bn in annual sales by 2025, far above the predicted sales for other blockbusters in this group, which will all amass $1–$2 billion in annual sales in the next six years.

Valentina Gburcik, senior director of cardiovascular and metabolic diseases, gender health and digital at GlobalData, comments: “The competitive pricing of the biosimilar drug will help its wider use, and the drug will steal a significant proportion of patient share from the mega-blockbuster Rituxan.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK